Immusoft

Immusoft is a biotechnology company based in Seattle, founded in 2009. The company specializes in developing immune cell technologies, particularly utilizing patients' B cells to create biofactories for delivering therapeutic proteins. This innovative approach aims to treat rare diseases and conditions, including HIV and Mucopolysaccharidosis type I (MPS I).

Immusoft is recognized for its immune system programming (ISP) technology, a gene therapy method that reprograms blood cells to produce therapeutic proteins. The company has achieved significant milestones, including FDA orphan drug and rare pediatric disease designations for its lead candidate, ISP-001, which is designed for MPS I patients. Immusoft has raised over $30 million in funding to support its research and development efforts, focusing on cell therapy platforms that provide sustained protein delivery without the need for lifelong immunosuppression.